1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Co., Ltd.

326030.KS
SK Biopharmaceuticals Co., Ltd.KR flagKorea Exchange
82,100.00
KRW
-2,800.00
- -
6.43TMarket Cap
SK Biopharmaceuticals Co., Ltd.
326030.KS
(Korea Exchange)

Recent

price

82,100.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
941.51
1,294.5
1,511.3
1,464.5
1,428.4
1,797.91
1,706.34
17.66
1,904.9
362.33
5,345.58
3,142.77
4,532.89
6,992.29
9,025.19
10,091.29
Revenue per Share
-487
-758
-1,025
-749
-579
-607
-1,953
-2,219
-1,100
-3,448
828
-1,780
-420
3,074
3,409
4,454.19
Basic EPS, GAAP
-463.69
-632.08
-1,098.22
-873.63
-651.13
-1,154.48
-1,999.8
-2,293.25
-1,467.03
-3,136.51
-1,262.37
-2,117.67
-1,244.7
1,040.37
1,874.96
1,723.78
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-6.67
-747.01
-1,780.08
-2,098.51
-2,667.06
-3,284.25
-5,237.28
-6,329.43
-7,174.16
-9,863.95
-8,299.51
-10,064.84
-10,504.25
-7,436.38
-4,022.41
-2,678.25
Book Value per Share
5,378.9
4,596.8
3,724.79
4,366.33
3,554.87
2,948.72
939.94
938.13
-213.92
5,008.26
5,430.41
3,821.93
3,754.21
6,913.88
9,897.57
11,194.13
Tangible Book Value per Share
40
40
40
49
50
50
50
62
65
72
78
78
78
78
78
78
Basic Weighted Avg Shares
37,631
51,798
60,455
72,441
71,417
89,928
85,316
1,099
123,852
25,999
418,645
246,179
354,892
547,596
706,741
790,250
Sales/Revenue/Turnover
-54.32
-69.48
-73.04
-54.17
-56.47
-64.13
-115.96
-12,660.28
-63.99
-921.18
22.68
-53.24
-10.57
17.59
28.86
33.92
Operating Margin (%)
5,174
5,759
5,249
4,341
4,567
3,085
3,165
3,342
6,501
10,859
11,642
12,984
15,317
17,428
16,947
16,249
Depreciation Expense
-19,465
-30,331
-41,002
-37,049
-28,949
-30,361
-97,649
-138,096
-71,519
-247,414
64,846
-139,431
-32,883
240,738
266,950
348,808
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.02
- -
- -
- -
- -
14.86
Effective Tax Rate (%)
-51.73
-58.56
-67.82
-51.14
-40.53
-33.76
-114.46
-12,568.64
-57.75
-951.63
15.49
-56.64
-9.27
43.96
37.77
44.14
Profit Margin (%)
152,627
138,106
96,183
156,497
122,395
133,376
34,850
50,588
-46,960
364,007
322,914
324,852
247,104
255,095
388,029
464,730
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
5,858
13,572
10,256
150,252
120,989
26,676
40,491
41,066
LT Debt
215,876
184,820
149,882
216,479
178,236
147,687
47,243
58,629
-13,025
379,067
444,187
316,560
320,951
573,984
826,270
932,052
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
20.1
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9.93
- -
- -
- -
- -
-56.51
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
8,228
8,429
8,916
LT Borrowings
- -
- -
- -
LT Finance Leases
41,144
40,491
41,066
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
78
78
78
Market Capitalization
7,937,251
9,753,269
7,423,798

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
642,858
683,229
776,881
Cash, Cash Equivalents & STI
256,165
309,482
310,861
Accounts Receivable, Net
230,316
228,826
294,061
Inventories
103,968
100,240
92,980
Total Current Liabilities
264,574
295,200
312,152
Payables & Accruals
- -
- -
- -
ST Debt
8,228
8,429
8,916
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-308.09%
22.53%
43.95%
Free Cash Flow
16.31%
-26.59%
80.21%
Net Income, GAAP
-87.32%
-267.77%
10.89%
Sales/Revenue/Turnover
1,261.19%
319.31%
29.06%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
113,975
133,995
136,602
163,025
547,596
2025
144,377
176,277
191,727
194,360
706,741
2026
227,886
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
164
359
123
- -
3,074
2025
298
420.32
946.67
- -
3,409
2026
1,343
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
IntelGenx Technologies Corp. (IGX.TO)
Vicore Pharma Holding AB (publ) (VICO.ST)
Lysogene S.A. (LYS.PA)
Jiangsu gdk Biotechnology Co., Ltd. (688670.SS)
Hangzhou Tigermed Consulting Co., Ltd (3347.HK)
Corium International, Inc. (CORI)
Business
SK Biopharmaceuticals Co., Ltd. SK Biopharmaceuticals Co., Ltd. engages in the research, development, and commercialization of innovative biopharmaceuticals targeting central nervous system disorders and oncology. Founded in 1993 and headquartered in Seongnam-si, South Korea, the company, a subsidiary of SK Inc., offers cenobamate (branded XCOPRI in the U.S. and ONTOZRY in Europe), an FDA-approved anti-seizure medication for partial-onset seizures in adults that it independently developed from discovery through U.S. commercialization via its own sales network; solriamfetol (SUNOSI), an FDA-approved treatment for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea commercialized through partnerships; and a pipeline including carisbamate in Phase 3 for Lennox-Gastaut syndrome, relenopride in Phase 2 for rare neurological diseases, SKL24741 and SKL-PSY in Phase 1 for epilepsy and bipolar disorder respectively, SKL20540 in Phase 1 for schizophrenia, SKL27969 for advanced solid tumors, and SKL13865 for attention deficit/hyperactivity disorder. It operates globally across North America, Europe, Asia, Central and South America, and the Middle East and North Africa, with subsidiaries like SK Life Science in the U.S. Recent developments include in-licensing a second radiopharmaceutical therapy asset targeting CA9 from WARF Therapeutics in November 2025 to expand its oncology portfolio following the 2024 SKL35501 (FL-091) deal from Full-Life Technologies, alongside supply agreements with TerraPower and PanTera for Actinium-225 isotopes and research collaborations with ProEn Therapeutics and Korea Institute of Radiological and Medical Sciences; launching a 50-50 U.S. joint venture with Eurofarma in June 2025 focused on AI-powered seizure prediction via the ZERO platform building on their 2022 cenobamate out-licensing in Latin America; acquiring SK Life Sciences Labs in 2023; extending U.S. cenobamate patents to 2032; and advancing Phase 3 trials of cenobamate in Northeast Asia while achieving over 100,000 patients treated worldwide. The company ventures into targeted protein degradation, radiopharmaceutical therapy, and cell and gene therapy to position as a leading global biotech.